Retrospective cohort analysis on predicting pulmonary fibrosis in elderly SARS-CoV-2-infected patients

回顾性队列分析预测老年SARS-CoV-2感染患者肺纤维化

阅读:1

Abstract

BACKGROUND: SARS-CoV-2 exhibits rapid transmission with a high susceptibility rate, particularly among the elderly. Pulmonary fibrosis (PF) following SARS-CoV-2 infection is a life-threatening complication. However, predictive models for PF in older patients are lacking. METHODS: Data from patients with COVID-19 aged 60 and above, collected retrospectively between November 2022 and November 2023 across two independent hospitals, were analyzed. Patients from Tangdu Hospital were divided into training and validation cohorts using a 7:3 allocation ratio, while those from The 940th Hospital of the Joint Logistics Support Force of the People's Liberation Army (PLA) served as the test cohort. Identify the most valuable predictors (MVPs) for PF using Least Absolute Shrinkage and Selection Operator (LASSO) regression, and construct a nomogram based on their regression coefficients derived from logistic regression. The calibration, clinical utility, and discriminatory ability of the nomogram were evaluated using the Hosmer-Lemeshow test, decision curve analysis (DCA), and Receiver Operating Characteristic (ROC) curve, respectively. RESULTS: Neutrophil percentage, C-reactive protein (CRP), gender, diagnostic classification, and time from symptom onset to hospitalization were identified as the MVPs for PF. The nomogram was developed based on these predictors, In all the three cohorts, the nomogram showed good calibration, clinical utility and discriminatory ability, with Area Under the Curve (AUC) of 0.777, 0.735 and 0.753, respectively. Furthermore, based on the principle of optimizing the balance between sensitivity and specificity, 131.026 was determined as the optimal cutoff value for the nomogram. Accordingly, patients with a nomogram score of 131.026 or higher were classified into the high-risk group. CONCLUSIONS: This study presents the first nomogram for predicting PF in elderly patients following SARS-CoV-2 infection, which may serve as a clinical tool for risk assessment and early management in this population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。